Early inducible nitric oxide synthase 2 (NOS 2) activity enhances ischaemic skin flap survival

Angiogenesis

Volumn 7, Issue 1, 2004, Pages 33-43

  Furuta, Sunao ^a   Vadiveloo, Peter ^b   Romeo Meeuw, Rosalind ^b   Morrison, Wayne ^b   Stewart, Alastair ^b   Mitchell, Geraldine ^b  

^a Suwa Red Cross Hospital   (Japan)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

angiogenesis; fibroblast growth factor 2; mast cells; nitric oxide; nitric oxide synthase 2 mice; nitric oxide synthase inhibitors; skin flap survival; vascular endothelial growth factor

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; INDUCIBLE NITRIC OXIDE SYNTHASE; METHYL ISOTHIOUREA; SODIUM CHLORIDE; UNCLASSIFIED DRUG; UREA DERIVATIVE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUTERIZATION; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ACTIVITY; EPIGASTRIC ARTERY; FEMALE; IMMUNOREACTIVITY; MALE; MAST CELL; MOUSE; NONHUMAN; PEDICLED SKIN FLAP; PRIORITY JOURNAL; SKIN FLAP SURVIVAL; SURGICAL TECHNIQUE; WILD TYPE; WOUND HEALING;

ANIMALS; CELL COMPARTMENTATION; CELL SURVIVAL; EPIGASTRIC ARTERIES; FIBROBLAST GROWTH FACTOR 2; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; ISCHEMIA; MICE; MICE, KNOCKOUT; MODELS, ANIMAL; NEOVASCULARIZATION, PHYSIOLOGIC; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE TYPE II; SKIN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WOUND HEALING;

ANIMALIA;

EID: 4344567206     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:AGEN.0000037328.86329.8b     Document Type: Article

References (42)

1. Kane AJ, Barker JE, Mitchell GM et al. Inducible nitric oxide synthase (iNOS) activity promotes ischaemic skin flap survival. Br J Pharmacol 2001; 132 (8): 1631-8.
2. Stewart AG, Phan LH, Grigoriadis G. Physiological and pathophysiological roles of nitric oxide. Microsurgery 1994; 15 (10): 693-702.
3. Pipili-Synetos E, Sakkoula E, Haralabopoulos G et al. Evidence that nitric oxide is an endogenous antiangiogenic mediator. Br J Pharmacol 1994; 111: 894-902.
4. Pipili-Synetos E, Papageorgiou A, Sakkoula E et al. Inhibition of angiogenesis, tumour growth and metastasis by the NO-releasing vasodilators, isosorbide mononitrate and dinitrate. Br J Pharmacol 1995; 116 (2): 1829-34.
5. Sakkoula E, Pipili-Synetos E, Maragoudakis ME. Involvement of nitric oxide in the inhibition of angiogenesis by interleukin-2. Br J Pharmacol 1997; 122 (5): 793-5.
6. Ziche M, Morbidelli L, Masini E et al. Nitric oxide promotes DNA synthesis and cyclic GMP formation in endothelial cells from postcapillary venules. Biochem Biophys Res Commun 1993; 192 (3): 1198-203.
7. Ziche M, Morbidelli L, Parenti A et al. Substance P increases cyclic GMP levels on coronary postcapillary venular endothelial cells. Life Sci 1993; 53 (14): PL229-34.
8. Gallo O, Masini E, Morbidelli L et al. Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst 1998; 90 (8): 587-96.
9. Konopka TE, Barker JE, Bamford TL et al. Nitric oxide synthase II gene disruption: Implications for tumor growth and vascular endothelial growth factor production. Cancer Res 2001; 61 (7): 3182-7.
10. Ziche M, Parenti A, Ledda F et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res 1997; 80 (6): 845-52.
11. Yamasaki K, Edington HD, McClosky C et al. Reversal of impaired wound repair in iNOS-deficient mice by topical adenoviral-mediated iNOS gene transfer. J Clin Invest 1998; 101 (5): 967-71.
12. Ruetten H, Thiemermann C. Prevention of the expression of inducible nitric oxide synthase by aminoguanidine or aminoethyl-isothiourea in macrophages and in the rat. Biochem Biophys Res Commun 1996; 225 (2): 525-30.
13. Southan GJ, Szabo C, Thiemermann C. Isothioureas: Potent inhibitors of nitric oxide synthases with variable isoform selectivity. Br J Pharmacol 1995; 114 (2): 510-6.
14. MacMicking JD, Nathan C, Hom G et al. Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase. Cell 1995; 81 (4): 641-50.
15. Nathan C. Inducible nitric oxide synthase: What difference does it make? J Clin Invest 1997; 100 (10): 2417-23.
16. Reichner JS, Meszaros AJ, Louis CA et al. Molecular and metabolic evidence for the restricted expression of inducible nitric oxide synthase in healing wounds. Am J Pathol 1999; 154 (4): 1097-104.
17. Frank S, Madlener M, Pfeilschifter J et al. Induction of inducible nitric oxide synthase and its corresponding tetrahydrobiopterin-cofactor-synthesizing enzyme GTP-cyclohydrolase I during cutaneous wound repair. J Invest Dermatol 1998; 111 (6): 1058-64.
18. Niwa K, Takizawa S, Kawaguchi C et al. Expression of inducible nitric oxide synthase immunoreactivity in rat brain following chronic hypoxia: Effect of aminoguanidine. Neurosci Lett 1999; 271 (2): 109-12.
19. Shimizu K, Naito S, Urata Y et al. Inducible nitric oxide synthase is expressed in granuloma pyogenicum. Br J Dermatol 1998; 138 (5): 769-73.
20. Cartwright JE, Johnstone AP, Whitley GS. Endogenously produced nitric oxide inhibits endothelial cell growth as demonstrated using novel antisense cell lines. Br J Pharmacol 2000; 131 (1): 131-7.
21. Sennlaub F, Courtois Y, Goureau O. Nitric oxide synthase-II is expressed in severe corneal alkali burns and inhibits neovascularization. Invest Ophthalmol Vis Sci 1999; 40 (12): 2773-9.
22. Pipili-Synetos E, Kritikou S, Papadimitriou E et al. Nitric oxide synthase expression, enzyme activity and NO production during angiogenesis in the chick chorioallantoic membrane. Br J Pharmacol 2000; 129 (1): 207-13.
23. Murohara T, Asahara T, Silver M et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest 1998; 101 (11): 2567-78.
24. Lee PC, Salyapongse AN, Bragdon GA et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol 1999; 277 (4 Pt 2): H1600-8.
25. Smith Jr, RS, Lin KF, Agata J et al. Human endothelial nitric oxide synthase gene delivery promotes angiogenesis in a rat model of hindlimb ischemia. Arterioscler Thromb Vasc Biol 2002; 22 (8): 1279-85.
26. Ziche M, Morbidelli L, Choudhuri R et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. J Clin Invest 1997; 99 (11): 2625-34.
27. Shukla A, Rasik AM, Shankar R. Nitric oxide inhibits wounds collagen synthesis. Mol Cell Biochem 1999; 200 (1-2): 27-33.
28. Naslund I, Norrby K. NO and de novo mammalian angiogenesis: Further evidence that NO inhibits bFGF-induced angiogenesis while not influencing VEGF165-induced angiogenesis. Apmis 2000; 108 (1): 29-37.
29. Fukumura D, Gohongi T, Kadambi A et al. Predominant role of endothelial nitric oxide synthase in vascular endothelial growth factor-induced angiogenesis and vascular permeability. Proc Natl Acad Sci USA 2001; 98 (5): 2604-9.
30. Papapetropoulos A, Desai KM, Rudic RD et al. Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. Am J Pathol 1997; 150 (5): 1835-44.
31. Joshi M, Fuller LR, Batchelor GC. L-arginine metabolites regulate DNA synthesis and nitric oxide synthase activity in cultured human dermal microvascular endothelial cells-potential positive and negative regulators of angiogenesis derived from L-arginine. Cancer Invest 1999; 17 (4): 235-44.
32. Messina A, Knight KR, Dowsing BJ et al. Localization of inducible nitric oxide synthase to mast cells during ischemia/reperfusion injury of skeletal muscle. Lab Invest 2000; 80 (3): 423-31.
33. Bidri M, Feger F, Varadaradjalou S et al. Mast cells as a source and target for nitric oxide. Int Immunopharmacol 2001; 1 (8): 1543-58.
34. Grutzkau A, Kruger-Krasagakes S, Baumeister H et al. Synthesis, storage, and release of vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) by human mast cells: Implications for the biological significance of VEGF206. Mol Biol Cell 1998; 9 (4): 875-84.
35. Qu Z, Liebler JM, Powers MR et al. Mast cells are a major source of basic fibroblast growth factor in chronic inflammation and cutaneous hemangioma. Am J Pathol 1995; 147 (3): 564-73.
36. Barker JE, Stewart AG. Differing effects of nitric oxide compared with peroxynitrite on mast cell degranulation in vitro. Br J Pharmacol 1998; 123: 305P.
37. Parenti A, Morbidelli L, Cui XL et al. Nitric oxide is an upstream signal of vascular endothelial growth factor-induced extracellular signal-regulated kinase 1/2 activation in postcapillary endothelium. J Biol Chem 1998; 273 (7): 4220-6.
38. Bouloumie A, Schini-Kerth VB, Busse R. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res 1999; 41 (3): 773-80.
39. Kroll J, Waltenberger J. VEGF-A induces expression of eNOS and iNOS in endothelial cells via VEGF receptor-2 (KDR). Biochem Biophys Res Commun 1998; 252 (3): 743-6.
40. Kostyk SK, Kourembanas S, Wheeler EL et al. Basic fibroblast growth factor increases nitric oxide synthase production in bovine endothelial cells. Am J Physiol 1995; 269 (5 Pt 2): H1583-9.
41. Babaei S, Teichert-Kuliszewska K, Monge JC et al. Role of nitric oxide in the angiogenic response in vitro to basic fibroblast growth factor. Circ Res 1998; 82 (9): 1007-15.
42. Bussolati B, Dunk C, Grohman M et al. Vascular endothelial growth factor receptor-1 modulates vascular endothelial growth factor-mediated angiogenesis via nitric oxide. Am J Pathol 2001; 159 (3): 993-1008.